Charting a new course for sustained metabolic health

Our Novel Approach to Sustained Metabolic Health

Developing new oral medicines for obesity and the resulting cardiometabolic diseases

Rivus is a clinical-stage biopharmaceutical company developing a new class of oral investigational medicines called Controlled Metabolic Accelerators (CMAs) for the treatment of obesity and resulting cardiometabolic diseases. Our CMAs are designed to safely increase metabolic rate to achieve sustained, fat-selective, muscle-preserving weight loss. 

With a robust dataset spanning three Phase 2 clinical trials, our lead candidate HU6 has demonstrated positive results and a well-tolerated safety profile in obese patients with MASLD (metabolic dysfunction-associated steatotic liver disease), MASH (metabolic dysfunction-associated steatohepatitis), and HFpEF (heart failure with preserved ejection fraction). These clinical indications are highly prevalent in individuals living with obesity and represent significant unmet needs.